Skip to main content

Szukaj

Reset all filters
365 Result(s)
Sortuj według

NASH

NASH

Niealkoholowe stłuszczeniowe zapalenie wątroby (NASH) jest jedną z głównych przyczyn włóknienia i marskości wątroby. Dowiedz się więcej.
Nadciśnienie tętnicze

Nadciśnienie tętnicze

Nadciśnienie tętnicze (wysokie ciśnienie krwi) to przypadłość, na którą cierpi około miliarda ludzi na świecie. Dowiedz się więcej.
Retinal health

Retinal health

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in Retinal Health.
Focus on Alliance Management

Focus on Alliance Management

Stefan Walke, Global Head of Alliance Management, dzieli się swoimi spostrzeżeniami dotyczącymi zarządzania aliansami i jego wkładem w rozwój udanych i długotrwałych partnerstw.
Be green Japan

Be green Japan

Boehringer Ingelheim's Yamagata site is gradually switching to a more sustainable energy supply.
Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
SIRPα Cancer Immunology Research

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Advancing regenerative medicine

Advancing regenerative medicine

Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Performance Indicators

Performance Indicators

Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Submit Your Opportunity

Submit Your Opportunity

Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
Championing novel science

Championing novel science

Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.